Trial · NCT02410551
Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
NCT02410551, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2018-10-05
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN). Trials, record NCT02410551. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02410551
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Pacritinib Before Transplant for Myeloproliferative Neoplasms (MPN)
- NCT number
- NCT02410551
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 4 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Myeloproliferative Diseases
- Interventions
- Pacritinib, Busulfan, Questionnaires, Phone Calls, Allogeneic Stem Cell Transplantation, Fludarabine
- First posted
- 2015-04-07
- Last updated
- 2018-10-30
- Results first posted
- 2018-10-05
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free Survival (PFS) | participants who received Pacritinib for >/= 60 days but less than 180 days who undergo transplant with a matched related or at least 7/8 matched unrelated donor. The protocol was to evaluate progression free survival at one year. | The protocol was to enroll at least 21 evaluable participants, defined as patients who received Pacritinib for \>/=60 days but less than 180 days. We enrolled four participants, however all four were not evaluable since no one was able to complete 60 days of Pacritinib. |
| Other | Evaluate Safety and Efficacy of Pacritinib. | Start of Pacritinib to one year post transplant | Evaluate safety and efficacy of this therapy determined by Neutrophil and platelet engraftment, Non-relapse mortality at one year post transplant, Overall survival at one year post transplant, Liver and spleen response to Pacritinib, Immune recovery, quality of life and symptom score, Primary and secondary graft failure,Complete remission, Relapse. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Progression-free Survival (PFS) | participants who received Pacritinib for >/= 60 days but less than 180 days who undergo transplant with a matched related or at least 7/8 matched unrelated donor. The protocol was to evaluate progression free survival at one year. | Four participants were not evaluable and no analysis was done. | ||
| OTHER_PRE_SPECIFIED | Evaluate Safety and Efficacy of Pacritinib. | Start of Pacritinib to one year post transplant | Four participants was invaluable and no analysis was done. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pacritinib Pre- Transplant | 4 | |
| Overall Study | COMPLETED | Pacritinib Pre- Transplant | 0 | |
| Overall Study | NOT COMPLETED | Pacritinib Pre- Transplant | 4 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Rash maculo-papular | Skin and subcutaneous tissue disorders | Pacritinib Pre- Transplant | 1 | 4 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pacritinib Pre- Transplant | 0 | 4 |
| Total, other adverse events | Pacritinib Pre- Transplant | 1 | 4 |
| Total, serious adverse events | Pacritinib Pre- Transplant | 0 | 4 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02410551
GET https://conductscience.org/api/trials/v1/NCT02410551/registered